Improving Assessment of Drug Safety Through Proteomics

Improving Assessment of Drug Safety Through Proteomics

BACKGROUND Early detection of adverse effects of novel therapies and understanding of their mechanisms could improve the safety and efficiency of drug development. We have retrospectively applied large-scale proteomics to blood samples from ILLUMINATE (Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events), a trial of torcetrapib (a cholesterol ester transfe...

Improving drug safety monitoring.

Drug safety monitoring is important in children. Young age, polypharmacy, prolonged hospitaliza-tion, being critically ill and use of unlicensed and off-label drugs have been identified as risk factors which predispose a child to experience an adverse drug reaction. In our country, the HIV/AIDS epidemic, setting up of intensive care units, increasing availability of imaging studies, and the int...

Improving patient safety through transparency.

that Congress will restore DSH to its previous level. And even such a restoration would not solve the underlying structural problem of poor targeting by states. Moreover, reopening DSH for debate could result in even bigger cuts. The second option is to create even clearer incentives for states to target their remaining DSH funds. CMS could retain the current framework for allocating states’ sh...

Application of Proteomics Technologies in the Drug Development Process

Application of Proteomics Technologies in the Drug Development Process